Nykode Therapeutics Is A Clinical Stage Biopharmaceutical Company Based In Oslonorwayfounded In 2006The Company Focuses On Developing Innovative Immunotherapies And Vaccines To Address Diseases With Significant Unmet Medical Needsparticularly In The Areas Of Cancer And Autoimmune Diseasesnykode Is Listed On The Oslo Stock Exchange Under The Ticker Nykd The Company Employs A Unique Modular Immunotherapy Technology Platform Called Vaccibodywhich Targets Antigens To Antigen Presenting Cellsapcs This Technology Aims To Induce Strong And Lasting Immune Responsesmaking It A Valuable Tool For Creating Effective Treatmentsnykode S Pipeline Includes Several Promising Candidatessuch As Vb10 16A Therapeutic Cancer Immunotherapy For Hpv16 Positive Cancersand Vb10 Neoan Individualized Neoantigen Immunotherapy In Phase 1B Trialsadditionallyvb10 Cov2 Is A Vaccine Candidate For Covid 19 Nykode Therapeutics Collaborates With Major Pharmaceutical Companies Like Rochegenentechand Regeneron To Enhance Its Research And Development Effortsreflecting Its Commitment To Advancing Innovative Therapeutic Solutions
No conferences found for this company.
| Company Name | Vaccibody As |
| Country |
Norway
|
| Address | N/A |
| Telephone | N/A |
| N/A |
